These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 24500564)

  • 1. The genetic and metabolic determinants of cardiovascular complications in type 2 diabetes: recent insights from animal models and clinical investigations.
    Kohen Avramoglu R; Laplante MA; Le Quang K; Deshaies Y; Després JP; Larose E; Mathieu P; Poirier P; Pérusse L; Vohl MC; Sweeney G; Ylä-Herttuala S; Laakso M; Uusitupa M; Marette A
    Can J Diabetes; 2013 Oct; 37(5):351-8. PubMed ID: 24500564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms linking diabetes to the accelerated development of atherosclerosis.
    Zeadin MG; Petlura CI; Werstuck GH
    Can J Diabetes; 2013 Oct; 37(5):345-50. PubMed ID: 24500563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease.
    De Taeye B; Smith LH; Vaughan DE
    Curr Opin Pharmacol; 2005 Apr; 5(2):149-54. PubMed ID: 15780823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding type 2 diabetes mellitus and associated cardiovascular disease: linked by insulin resistance.
    Tennyson GE
    Am J Manag Care; 2002 Oct; 8(16 Suppl):S450-9. PubMed ID: 12408408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene regulatory network reveals oxidative stress as the underlying molecular mechanism of type 2 diabetes and hypertension.
    Jesmin J; Rashid MS; Jamil H; Hontecillas R; Bassaganya-Riera J
    BMC Med Genomics; 2010 Oct; 3():45. PubMed ID: 20942928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular clocks, type 2 diabetes and cardiovascular disease.
    Prasai MJ; George JT; Scott EM
    Diab Vasc Dis Res; 2008 Jun; 5(2):89-95. PubMed ID: 18537095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visceral adipose tissue accumulation and cardiovascular disease risk profile in postmenopausal women with impaired glucose tolerance or type 2 diabetes.
    Lemieux S; Bédard A; Piché MÈ; Weisnagel SJ; Corneau L; Bergeron J
    Clin Endocrinol (Oxf); 2011 Mar; 74(3):340-5. PubMed ID: 21092050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation and type 2 diabetes.
    Calle MC; Fernandez ML
    Diabetes Metab; 2012 Jun; 38(3):183-91. PubMed ID: 22252015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes.
    Sullivan TJ; Miao Z; Zhao BN; Ertl LS; Wang Y; Krasinski A; Walters MJ; Powers JP; Dairaghi DJ; Baumgart T; Seitz LC; Berahovich RD; Schall TJ; Jaen JC
    Metabolism; 2013 Nov; 62(11):1623-32. PubMed ID: 23953944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin resistance, diabetes, and cardiovascular risk.
    Paneni F; Costantino S; Cosentino F
    Curr Atheroscler Rep; 2014 Jul; 16(7):419. PubMed ID: 24781596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin resistance--a common link between type 2 diabetes and cardiovascular disease.
    Lebovitz HE
    Diabetes Obes Metab; 2006 May; 8(3):237-49. PubMed ID: 16634983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intra-abdominal obesity: an untreated risk factor for Type 2 diabetes and cardiovascular disease.
    Després JP
    J Endocrinol Invest; 2006; 29(3 Suppl):77-82. PubMed ID: 16751711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel biological insights emerging from genetic studies of type 2 diabetes and related metabolic traits.
    De Silva NM; Frayling TM
    Curr Opin Lipidol; 2010 Feb; 21(1):44-50. PubMed ID: 19956073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of grape seed extract in Type 2 diabetic subjects at high cardiovascular risk: a double blind randomized placebo controlled trial examining metabolic markers, vascular tone, inflammation, oxidative stress and insulin sensitivity.
    Kar P; Laight D; Rooprai HK; Shaw KM; Cummings M
    Diabet Med; 2009 May; 26(5):526-31. PubMed ID: 19646193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The IL-1 Pathway in Type 2 Diabetes and Cardiovascular Complications.
    Herder C; Dalmas E; Böni-Schnetzler M; Donath MY
    Trends Endocrinol Metab; 2015 Oct; 26(10):551-563. PubMed ID: 26412156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes.
    Samaras K; Botelho NK; Chisholm DJ; Lord RV
    Obesity (Silver Spring); 2010 May; 18(5):884-9. PubMed ID: 20019678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGF21: a novel prospect for the treatment of metabolic diseases.
    Kharitonenkov A; Shanafelt AB
    Curr Opin Investig Drugs; 2009 Apr; 10(4):359-64. PubMed ID: 19337957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The obese patient with diabetes mellitus: from research targets to treatment options.
    Sharma AM
    Am J Med; 2006 May; 119(5 Suppl 1):S17-23. PubMed ID: 16563943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidative stress and diabetic cardiovascular disorders: roles of mitochondria and NADPH oxidase.
    Shen GX
    Can J Physiol Pharmacol; 2010 Mar; 88(3):241-8. PubMed ID: 20393589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of β-cell function: a translational journey from the bench to the bedside.
    Goldfine AB; Kulkarni RN
    Diabetes Obes Metab; 2012 Oct; 14 Suppl 3():152-60. PubMed ID: 22928576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.